SCHEMBL3242897

SCHEMBL3242897

O=C(c1ccc(NCc2ccc(F)c(Cl)c2)cc1)N1CCCCC1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.54
ALDH1A1 P00352 4/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
HSD11B1 P28845 2/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
HPGD P15428 6/20 0.48
HTR1A P08908 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
NTRK1 P04629 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3237674 0.89 HPGD (0.59) MAPTALDH1A1L3MBTL1HSD11B1NPC1
SCHEMBL3242896 0.86 MAPT (0.54) MAPTALDH1A1L3MBTL1HSD11B1NPC1
SCHEMBL3259882 0.85 ALDH1A1 (0.70) MAPTALDH1A1L3MBTL1HSD11B1NPC1
SCHEMBL3241843 0.83 NPC1 (0.63) MAPTALDH1A1L3MBTL1HSD11B1NPC1
SCHEMBL2653348 0.78 HPGD (0.73) MAPTALDH1A1HSD11B1HPGDHTR1A
SCHEMBL1711101 0.77 SLC6A7 (0.67) MAPTALDH1A1L3MBTL1NPC1RAB9A
SCHEMBL2075037 0.75 HPGD (0.68) MAPTALDH1A1HSD11B1HPGDHTR1A
SCHEMBL3237671 0.75 HPGD (0.59) MAPTALDH1A1L3MBTL1HSD11B1HPGD
SCHEMBL3268298 0.75 HPGD (0.44) MAPTALDH1A1L3MBTL1HSD11B1NPC1
SCHEMBL912044 0.71 MEN1 (0.50) MAPTALDH1A1L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 MAPT 3110/4885ALDH1A1 1588/4885L3MBTL1 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.